(Q39137614)

9 September 2017

title

Activation of ERK1/2 and Akt is associated with cisplatin resistance in human lung cancer cells (English)

1 reference

9 September 2017

1 reference

1 reference

Mei Wang

1

1 reference

9 September 2017

Zi Min Liu

2

1 reference

9 September 2017

Xiang Chun Li

3

1 reference

9 September 2017

Yi Tang Yao

4

1 reference

9 September 2017

Zong Xiu Yin

5

1 reference

9 September 2017

publication date

1 June 2013

1 reference

9 September 2017

published in

Journal of Chemotherapy

1 reference

9 September 2017

volume

25

1 reference

9 September 2017

issue

3

1 reference

9 September 2017

page(s)

162-169

1 reference

American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003.

9 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1179%2F1973947812Y.0000000056

The resurgence of platinum-based cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947812Y.0000000056

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947812Y.0000000056

Mechanisms of resistance to cisplatin and carboplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947812Y.0000000056

ERK1/2 is highly phosphorylated in melanoma metastases and protects melanoma cells from cisplatin-mediated apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947812Y.0000000056

Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947812Y.0000000056

ERK/BCL-2 pathway in the resistance of pancreatic cancer to anoikis

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947812Y.0000000056

Activation of the PI3K pathway in cancer through inhibition of PTEN by exchange factor P-REX2a

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947812Y.0000000056

FKBP51 affects cancer cell response to chemotherapy by negatively regulating Akt.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947812Y.0000000056

AKT is activated in an ataxia-telangiectasia and Rad3-related-dependent manner in response to temozolomide and confers protection against drug-induced cell growth inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947812Y.0000000056

Complicating the complexity of p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947812Y.0000000056

Inhibition of AKT2 enhances sensitivity to gemcitabine via regulating PUMA and NF-κB signaling pathway in human pancreatic ductal adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947812Y.0000000056

Akt promotes cisplatin resistance in human ovarian cancer cells through inhibition of p53 phosphorylation and nuclear function

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947812Y.0000000056

Present status and problems on molecular targeted therapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947812Y.0000000056

Acquisition of chemoresistance in intrahepatic cholangiocarcinoma cells by activation of AKT and extracellular signal-regulated kinase (ERK)1/2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947812Y.0000000056

Tumour cell survival signalling by the ERK1/2 pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947812Y.0000000056

Prognostic and predictive values of pERK1/2 and pAkt-1 expression in non-small cell lung cancer patients treated with adjuvant chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947812Y.0000000056

PKC 412 sensitizes U1810 non-small cell lung cancer cells to DNA damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947812Y.0000000056

Combining targeted therapies and drugs with multiple targets in the treatment of NSCLC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947812Y.0000000056

10.1179/1973947812Y.0000000056

21 January 2018

Identifiers

DOI

1 reference

release_vdfl76hvm5efzizvogcmmvf3ta

9 September 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/vdfl76hvm5efzizvogcmmvf3ta

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference